Zacks Investment Research Lowers BioSpecifics Technologies Corp (BSTC) to Sell
Zacks Investment Research cut shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) from a hold rating to a sell rating in a research note issued to investors on Monday, May 15th.
According to Zacks, “BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. “
BioSpecifics Technologies Corp (BSTC) traded down 0.08% on Monday, hitting $48.15. The stock had a trading volume of 65,672 shares. BioSpecifics Technologies Corp has a one year low of $35.59 and a one year high of $58.79. The firm has a market cap of $345.28 million, a price-to-earnings ratio of 29.54 and a beta of 1.77. The company’s 50-day moving average price is $52.57 and its 200 day moving average price is $52.76.
BioSpecifics Technologies Corp (NASDAQ:BSTC) last released its quarterly earnings data on Wednesday, March 15th. The biopharmaceutical company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.02. The business had revenue of $6.62 million during the quarter, compared to the consensus estimate of $6.76 million. BioSpecifics Technologies Corp had a return on equity of 21.70% and a net margin of 43.43%. Analysts expect that BioSpecifics Technologies Corp will post $1.73 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the company. Isthmus Partners LLC boosted its stake in shares of BioSpecifics Technologies Corp by 2.0% in the third quarter. Isthmus Partners LLC now owns 17,741 shares of the biopharmaceutical company’s stock worth $782,000 after buying an additional 346 shares during the period. US Bancorp DE boosted its stake in shares of BioSpecifics Technologies Corp by 14.7% in the third quarter. US Bancorp DE now owns 3,470 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 445 shares during the period. BlackRock Advisors LLC boosted its stake in shares of BioSpecifics Technologies Corp by 1.3% in the third quarter. BlackRock Advisors LLC now owns 26,070 shares of the biopharmaceutical company’s stock worth $1,191,000 after buying an additional 332 shares during the period. Two Sigma Securities LLC acquired a new stake in shares of BioSpecifics Technologies Corp during the third quarter worth $209,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of BioSpecifics Technologies Corp during the fourth quarter worth $1,658,000. 55.74% of the stock is owned by hedge funds and other institutional investors.
About BioSpecifics Technologies Corp
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related stocks with our FREE daily email newsletter.